ArticleRheumatology advances in practice2026
Correlation of vascular enhancement on MRI and clinical manifestations in patients with GCA.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: GCA has diverse cranial manifestations, and cranial vessel MRI (cvMRI) can assess multiple arteries simultaneously. We aimed to determine whether vessel-specific enhancement on cvMRI correlates with clinical manifestations and diagnosis in GCA. Methods: We conducted a retrospective cohort study of patients who underwent cvMRI for suspected GCA at a single academic centre. We assessed associations between vessel wall enhancement on cvMRI and anatomically expected GCA symptoms. We used univariate and multivariable logistic regression adjusting for age, sex and glucocorticoid exposure to assess the relationship between vessel abnormalities and a diagnosis of GCA. Results: Among 439 patients, 153 (34.9%) were diagnosed with GCA. Median time (quartile 1 [Q1]-quartile 3 [Q3]) from glucocorticoid initiation to cvMRI was 11.5 days (Q1-Q3: 5.8-207.2). Maxillary and ophthalmic artery involvement were specific but insensitive for jaw claudication and vision loss, respectively (specificity 87.1%, 95% CI, 80.3-93.9 and 72.6%, 95% CI, 61.5-83.7; sensitivity 40.0%, 95% CI, 26.5-51.4 and 43.3%, 95% CI, 33.1-53.6, respectively). Headache showed no association with specific vessels. Any arterial enhancement was associated with GCA in univariate analysis, but only temporal artery involvement was predictive in multivariable analysis (odds ratio [OR] 5.20, 95% CI, 1.65-16.88), particularly when bilateral (OR 9.82, 95% CI, 2.82-38.32). Conclusion: Temporal artery enhancement remains the strongest imaging correlate for a diagnosis of GCA. Vessel-specific enhancement on cvMRI correlates with vision loss and jaw claudication but not headache. cvMRI may aid diagnosis in diagnostically uncertain cases, even after glucocorticoid initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.